Prediction of Preterm Delivery Using Serum Ischemia Modified Albumin, Biglycan, and Decorin Levels in Women with Threatened Preterm Labor

The serum ischemia modified albumin (IMA), biglycan, and decorin levels of pregnant women who were hospitalized for threatened preterm labor were measured.  Fifty-one consecutive pregnant women with a single pregnancy between the 24 and 36 weeks with a diagnosis of threatened preterm labor were incl...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Revista Brasileira de ginecologia e obstetrícia 2023-12, Vol.45 (12), p.e754-e763
Hauptverfasser: Biyik, Ismail, Soysal, Cenk, Ince, Ozlem Ulas Onur, Durmus, Sinem, Oztas, Efser, Keskin, Nadi, Isiklar, Ozben Ozden, Karaagac, Oğuz Han, Gelisgen, Remise, Uzun, Hafize
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The serum ischemia modified albumin (IMA), biglycan, and decorin levels of pregnant women who were hospitalized for threatened preterm labor were measured.  Fifty-one consecutive pregnant women with a single pregnancy between the 24 and 36 weeks with a diagnosis of threatened preterm labor were included in the present prospective cohort study.  As a result of multivariate logistic regression analysis for predicting preterm delivery within 24 hours, 48 hours, 7 days, 14 days, ≤ 35 gestational weeks, and ≤ 37 gestational weeks after admission, area under the curve (AUC) (95% confidence interval [CI[) values were 0.95 (0.89-1.00), 0.93 (0.86-0.99), 0.91 (0.83-0.98), 0.92 (0.85-0.99), 0.82 (0.69-0.96), and 0.89 (0.80-0.98), respectively. In the present study, IMA and biglycan levels were found to be higher and decorin levels lower in women admitted to the hospital with threatened preterm labor and who gave preterm birth within 48 hours compared with those who gave birth after 48 hours.  In pregnant women admitted to the hospital with threatened preterm labor, the prediction preterm delivery of the combined model created by adding IMA, decorin, and biglycan in addition to the TVS CL measurement was higher than the TVS CL measurement alone.  The present trial was registered at ClinicalTrials.gov, number NCT04451928.
ISSN:0100-7203
1806-9339
1806-9339
DOI:10.1055/s-0043-1772593